Cargando…
Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
Objectives: Clinical trials in psychiatry frequently report results from lengthy, comprehensive assessments to characterize a subject emotionally, cognitively, and behaviorally before and after treatment. However, the potential treatment implications of these results and how they translate into clin...
Autores principales: | Nasser, Azmi, Kosheleff, Alisa R., Hull, Joseph T., Liranso, Tesfaye, Qin, Peibing, Busse, Gregory D., O'Neal, Welton, Fava, Maurizio, Faraone, Stephen V., Rubin, Jonathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8066343/ https://www.ncbi.nlm.nih.gov/pubmed/33600233 http://dx.doi.org/10.1089/cap.2020.0148 |
Ejemplares similares
-
Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended‐release in children and adolescents with attention‐deficit/hyperactivity disorder
por: Nasser, Azmi, et al.
Publicado: (2021) -
Viloxazine in the Treatment of Attention Deficit Hyperactivity Disorder
por: Edinoff, Amber N., et al.
Publicado: (2021) -
Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021) -
Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN‐812 (Viloxazine Extended‐Release) Pharmacokinetics in Healthy Adults
por: Wang, Zhao, et al.
Publicado: (2021) -
Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
por: Price, Maxwell Z., et al.
Publicado: (2023)